Replies to post #92127 on Biotech Values

[ghmm]

ITMN/Roche:

It looks like the agreement was amended again per the 10-k in November. I don't have your skills to fill in the missing parts but it seems they have 2 compounds they are ready to advance.

http://www.sec.gov/Archives/edgar/data/1087432/000119312510055752/dex1074.htm

EDIT:

This is from the main body of the 10-k (page 14)
http://www.sec.gov/Archives/edgar/data/1087432/000119312510055752/d10k.htm

In November 2008 and October 2009, we amended the Collaboration Agreement among other things to extend the research program (and consequently the research exclusivity period whereby each party is prohibited from engaging in certain competitive research activities) for an additional amount of time and to provide for certain funding by Roche of activities taking place during such extended research period. Such research funding by Roche may be credited by Roche against certain future payments in connection with Roche’s inclusion of possible additional compounds as part of its license rights granted to it under the collaboration